nr

NR1H4 activator 1 is a potent and selective agonist of the Famesoid X Receptor (FXR).

Tat-NR2B9c (NA-1) is a postsynaptic density-95 (PSD-95) inhibitor with neuroprotective and antiepileptic effects.Tat-NR2B9c inhibits PSD-95d2, PSD-95d1, and PSD-95, which prevents the activation of NMDA-induced NADPH oxidase in neurons, thereby blocking the production of superoxide, which reduces ischemic injury in the acute phase after stroke.

Tat-NR2B9c TFA is a 20-aa peptide, and acts as an inhibitor of postsynaptic density-95 (PSD-95)(EC50 of 6.7 nM for PSD-95d2), and possesses neuroprotective efficacy.

Tat-NR2B9c acetate (NA-1 acetate) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c acetate disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c acetate also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy.

Rheb inhibitor NR1 is a selective mTORC1 inhibitor that suppresses the phosphorylation of T389pS6K1 and enhances the phosphorylation of S473pAKT.

Tat-NR2BAA is an inactive control peptide of Tat-NR2B9c. It shares a similar sequence with Tat-NR2B9c, but possesses a double-point mutation in the COOH terminal tSXV motif. This mutation renders Tat-NR2BAA unable to bind PSD-95. Tat-NR2B9c, on the other hand, is a membrane-permeable peptide that interferes with PSD-95/NMDAR binding. This interference leads to the decoupling of NR2B- and/or NR2A-type NMDARs from PSD-95[1][2].

NR-160 is a selective HDAC6 inhibitor (IC₅₀=30 nM) with low cytotoxicity against leukemia cell lines.

NR-6A is a PROTAC designed to target p38.

NR 7h is a potent and selective degrader of p38α and p38β, exhibiting DC50 values of 24 nM for p38α in T47D cells and 27.2 nM in MB-MDA-231 cells, respectively [1].

(R)-Viloxazine Hydrochloride is the R-isomer of Viloxazine, a selective norepinephrine reuptake inhibitor (NRI) used as an antidepressant.

NR-V04 is a PROTAC degrader targeting NR4A1.

NR-11c is a selective and potent p38α PROTAC degrader. It effectively degrades p38α in various tumor cells. When administered to mice via intraperitoneal or tail vein injection, NR-11c primarily acts in the liver. It is used for cancer research.

NR-NO2 is a prospective therapeutic agent with targeted delivery and image-guided capability for use in antitumor studies, also demonstrating antibacterial effects [1].

SRC-1 NR box peptide acetate is a bioactive peptide, consisting of a 14-amino acid fragment derived from the steroid receptor coactivator SRC-1 NR II. This compound is useful for investigating the regulatory mechanisms of estrogen receptor ligands.

NR6 is an innovative and potent ALDH1A3 inhibitor with high selectivity. It effectively suppresses the growth of mesothelioma multicellular spheroids and the recruitment of neutrophils.

NR2F6 modulator-2 (Compound I) is an effective NR2F6 modulator that inhibits the recruitment of endogenous NSD1 peptides, with an IC50 equivalent to 2 equivalents of NR2F6. It is applicable in cancer and immunology research.

NR4A1 agonist 1 is an NR4A1 agonist with a Ki value of 2.96 μM. It demonstrates significant lipid-lowering activity in 3T3-L1 adipocytes, with an EC50 of 0.13 μM, effectively reducing triglyceride (TG) accumulation and lipid droplet formation. NR4A1 agonist 1 is applicable in obesity-related research.

NR1H3 modulator-1 is a regulator of NR1H3.

NR2F6 modulator-1 is a potent modulator of nuclear receptor subfamily 2, group F, member 6 (NR2F6), used to study immune regulation and modulation of tumour stem cell activity.

NR2F1 agonist 1, a specific nuclear receptor NR2F1 activator, initiates dormancy programs in cancer cells by upregulating NR2F1 and its target genes controlling dormancy. This compound promotes neural crest-like features and suppresses growth in head and neck squamous cell carcinoma (HNSCC) through NR2F1 activation. Moreover, NR2F1 agonist 1 demonstrates tumor growth inhibition in a mouse primary tumor model.

Tat-NR2BAA TFA serves as the inactive control peptide for Tat-NR2B9c, featuring a comparable sequence with a crucial distinction: a double-point mutation in its COOH-terminal tSXV motif. This alteration renders Tat-NR2BAA TFA unable to bind to PSD-95, in contrast to Tat-NR2B9c. The latter is a membrane-permeant peptide that impedes PSD-95/NMDAR interaction, specifically detaching NR2B- and/or NR2A-type NMDARs from PSD-95 [1].

Tat-HA-NR2B9, comprising an HIV-1 Tat transduction domain fragment, an influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c), has demonstrated efficacy in reducing infarct size and enhancing neurological function following ischemia-induced cerebral injury in rats [1].

NR2E3 agonist 1 is a small molecule photoreceptor-specific nuclear receptor (NR2E3) agonist with antitumor activity for the study of diseases caused by abnormalities in photoreceptor cell-specific receptors.

Anakinra (Raleukin) is a cytokine inactivator and interleukin 1 receptor antagonist that can be used to study secondary phagocytic lymphohistiocytosis and rheumatoid arthritis.